A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control
Phase of Trial: Phase III
Latest Information Update: 09 Aug 2018
At a glance
- Drugs Sitagliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 04 Aug 2018 Planned number of patients changed from 190 to 220.
- 29 Jun 2018 Planned number of patients changed from 170 to 190.
- 11 Oct 2017 Planned End Date changed from 28 Jan 2019 to 23 Jan 2020.